IL157086A0 - Multivalent ligand complexes - Google Patents

Multivalent ligand complexes

Info

Publication number
IL157086A0
IL157086A0 IL15708603A IL15708603A IL157086A0 IL 157086 A0 IL157086 A0 IL 157086A0 IL 15708603 A IL15708603 A IL 15708603A IL 15708603 A IL15708603 A IL 15708603A IL 157086 A0 IL157086 A0 IL 157086A0
Authority
IL
Israel
Prior art keywords
ligand complexes
multivalent ligand
multivalent
complexes
ligand
Prior art date
Application number
IL15708603A
Other languages
English (en)
Original Assignee
Guy Patchornik
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guy Patchornik filed Critical Guy Patchornik
Priority to IL15708603A priority Critical patent/IL157086A0/xx
Publication of IL157086A0 publication Critical patent/IL157086A0/xx
Priority to CNA2004800263533A priority patent/CN101415721A/zh
Priority to SG200806175-6A priority patent/SG145760A1/en
Priority to MXPA06000944A priority patent/MXPA06000944A/es
Priority to KR1020067000635A priority patent/KR20060037337A/ko
Priority to PCT/IL2004/000669 priority patent/WO2005010141A2/en
Priority to RU2006105648/13A priority patent/RU2006105648A/ru
Priority to EP04745009A priority patent/EP1648995A4/en
Priority to JP2006520982A priority patent/JP2007515384A/ja
Priority to CA002531492A priority patent/CA2531492A1/en
Priority to ZA200600315A priority patent/ZA200600315B/xx
Priority to US11/330,112 priority patent/US20060121519A1/en
Priority to IL173107A priority patent/IL173107A0/en
Priority to NO20060400A priority patent/NO20060400L/no
Priority to US11/826,906 priority patent/US7956165B2/en
Priority to US13/083,634 priority patent/US20110256525A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL15708603A 2003-07-24 2003-07-24 Multivalent ligand complexes IL157086A0 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
IL15708603A IL157086A0 (en) 2003-07-24 2003-07-24 Multivalent ligand complexes
CA002531492A CA2531492A1 (en) 2003-07-24 2004-07-22 Compositions for purifying and crystallizing molecules of interest
RU2006105648/13A RU2006105648A (ru) 2003-07-24 2004-07-22 Композиции для очистки и кристаллизации представляющих интерес молекул
JP2006520982A JP2007515384A (ja) 2003-07-24 2004-07-22 目的とする分子を精製および結晶化するための組成物
MXPA06000944A MXPA06000944A (es) 2003-07-24 2004-07-22 Composiciones para purificar y cristalizar moleculas de interes.
KR1020067000635A KR20060037337A (ko) 2003-07-24 2004-07-22 관심의 대상이 되는 분자를 정제 및 결정화하기 위한조성물
PCT/IL2004/000669 WO2005010141A2 (en) 2003-07-24 2004-07-22 Compositions for purifying and crystallizing molecules of interest
CNA2004800263533A CN101415721A (zh) 2003-07-24 2004-07-22 用于纯化和结晶目的分子的组合物
EP04745009A EP1648995A4 (en) 2003-07-24 2004-07-22 COMPOSITIONS FOR PURIFYING AND CRYSTALLIZING MOLECULES DATA
SG200806175-6A SG145760A1 (en) 2003-07-24 2004-07-22 Compositions for purifying and crystallizing molecules of interest
IL173107A IL173107A0 (en) 2003-07-24 2006-01-12 Compositions and methods for purifying and crystallizing molecules of interest
ZA200600315A ZA200600315B (en) 2003-07-24 2006-01-12 Compositions for purifying and crystallizing molecules of interest
US11/330,112 US20060121519A1 (en) 2003-07-24 2006-01-12 Compositions and methods for purifying and crystallizing molecules of interest
NO20060400A NO20060400L (no) 2003-07-24 2006-01-25 Sammensetninger for rensing og krystallisering av molekyler av interesse
US11/826,906 US7956165B2 (en) 2003-07-24 2007-07-19 Compositions and methods for purifying and crystallizing molecules of interest
US13/083,634 US20110256525A1 (en) 2003-07-24 2011-04-11 Compositions and methods for purifying and crystallizing molecules of interest

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL15708603A IL157086A0 (en) 2003-07-24 2003-07-24 Multivalent ligand complexes

Publications (1)

Publication Number Publication Date
IL157086A0 true IL157086A0 (en) 2004-02-08

Family

ID=32652285

Family Applications (2)

Application Number Title Priority Date Filing Date
IL15708603A IL157086A0 (en) 2003-07-24 2003-07-24 Multivalent ligand complexes
IL173107A IL173107A0 (en) 2003-07-24 2006-01-12 Compositions and methods for purifying and crystallizing molecules of interest

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL173107A IL173107A0 (en) 2003-07-24 2006-01-12 Compositions and methods for purifying and crystallizing molecules of interest

Country Status (13)

Country Link
US (1) US20060121519A1 (cg-RX-API-DMAC7.html)
EP (1) EP1648995A4 (cg-RX-API-DMAC7.html)
JP (1) JP2007515384A (cg-RX-API-DMAC7.html)
KR (1) KR20060037337A (cg-RX-API-DMAC7.html)
CN (1) CN101415721A (cg-RX-API-DMAC7.html)
CA (1) CA2531492A1 (cg-RX-API-DMAC7.html)
IL (2) IL157086A0 (cg-RX-API-DMAC7.html)
MX (1) MXPA06000944A (cg-RX-API-DMAC7.html)
NO (1) NO20060400L (cg-RX-API-DMAC7.html)
RU (1) RU2006105648A (cg-RX-API-DMAC7.html)
SG (1) SG145760A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005010141A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200600315B (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7956165B2 (en) 2003-07-24 2011-06-07 Affisink Biotechnology Ltd. Compositions and methods for purifying and crystallizing molecules of interest
WO2006085321A2 (en) * 2005-02-10 2006-08-17 Affisink Biotechnology Ltd. Compositions and methods for purifying and crystallizing molecules of interest
FR2902799B1 (fr) 2006-06-27 2012-10-26 Millipore Corp Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
US8163886B2 (en) * 2006-12-21 2012-04-24 Emd Millipore Corporation Purification of proteins
US8569464B2 (en) 2006-12-21 2013-10-29 Emd Millipore Corporation Purification of proteins
US8362217B2 (en) 2006-12-21 2013-01-29 Emd Millipore Corporation Purification of proteins
WO2009064425A1 (en) * 2007-11-13 2009-05-22 Rational Affinity Devices, L.L.C. Multistate affinity ligands for the separation and purification of antibodies, antibody fragments and conjugates of antibodies and antibody fragments
CA2708836A1 (en) * 2007-12-17 2009-06-25 Affisink Biotechnology Ltd. Methods for purifying or depleting molecules or cells of interest
WO2009151514A1 (en) 2008-06-11 2009-12-17 Millipore Corporation Stirred tank bioreactor
DK2370561T3 (da) 2008-12-16 2019-10-21 Emd Millipore Corp Omrøringstankreaktor og fremgangsmåde
KR101855714B1 (ko) 2010-03-05 2018-05-10 베링거 인겔하임 인터내셔날 게엠베하 항체의 선택적 농축
CN102892791B (zh) 2010-05-17 2017-05-17 Emd密理博公司 用于纯化生物分子的刺激响应性聚合物
US10030224B2 (en) 2015-11-01 2018-07-24 Ariel-University Research And Development Company Ltd. Methods of analyzing cell membranes
WO2021152584A1 (en) 2020-01-28 2021-08-05 Ariel Scientific Innovations Ltd. Methods of analyzing cell membranes

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036945A (en) * 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US5215927A (en) * 1986-01-30 1993-06-01 Fred Hutchinson Cancer Research Center Method for immunoselection of cells using avidin and biotin
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US6740734B1 (en) * 1994-01-14 2004-05-25 Biovitrum Ab Bacterial receptor structures
SE9400088D0 (sv) * 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US6017719A (en) * 1994-06-14 2000-01-25 Nexell Therapeutics, Inc. Positive and positive/negative cell selection mediated by peptide release
US20010008766A1 (en) * 1998-03-17 2001-07-19 Sylvia Daunert Quantitative binding assays using green fluorescent protein as a label
US6589503B1 (en) * 1998-06-20 2003-07-08 Washington University Membrane-permeant peptide complexes for medical imaging, diagnostics, and pharmaceutical therapy
US7198930B2 (en) * 2000-02-29 2007-04-03 Millennium Pharmaceuticals, Inc. Human protein kinase, phosphatase, and protease family members and uses thereof
JP5398945B2 (ja) * 2001-04-23 2014-01-29 マリンクロッド エルエルシー TcおよびRe標識放射活性グリコシル化オクトレオチド誘導体
US20040265921A1 (en) * 2003-06-30 2004-12-30 National University Of Singapore Intein-mediated attachment of ligands to proteins for immobilization onto a support
US7956165B2 (en) * 2003-07-24 2011-06-07 Affisink Biotechnology Ltd. Compositions and methods for purifying and crystallizing molecules of interest

Also Published As

Publication number Publication date
US20060121519A1 (en) 2006-06-08
JP2007515384A (ja) 2007-06-14
KR20060037337A (ko) 2006-05-03
WO2005010141A3 (en) 2009-03-26
SG145760A1 (en) 2008-09-29
ZA200600315B (en) 2007-04-25
EP1648995A4 (en) 2010-03-10
CN101415721A (zh) 2009-04-22
IL173107A0 (en) 2006-06-11
RU2006105648A (ru) 2006-07-27
MXPA06000944A (es) 2006-03-30
EP1648995A2 (en) 2006-04-26
WO2005010141A2 (en) 2005-02-03
CA2531492A1 (en) 2005-02-03
NO20060400L (no) 2006-03-27

Similar Documents

Publication Publication Date Title
IL174020A0 (en) Antigen-scaffold complexes
EP1859656A4 (en) ORGANOMETALLIC COMPLEXES
AU2003216341A8 (en) Mhc-peptide complex binding ligands
ZA200602792B (en) Multigame selection
ZA200500435B (en) 1-heterocyclyalkyl-3-sulfonylindole or -indazole derivatves as 5-hydroxytryptamine-6 ligands
GB0313132D0 (en) Peptide ligands
ZA200506416B (en) Heterocyclyl-3-sulfonylindazoles as 5-hydroxytryptamine-6 ligands
GB0323190D0 (en) Bed
EP1834363A4 (en) ORGANOMETALLIC COMPLEXES
GB0426903D0 (en) Complexes and methods
GB0218675D0 (en) Nitrogen-containing ligands
GB0424468D0 (en) Electroluminescent complexes
IL173265A0 (en) Imidazo-pyrimidines and triazolo-pyrimidines: benzodiazcpine receptor ligands
GB0230202D0 (en) Ligand
GB0414998D0 (en) Monodonor ligands
GB0313709D0 (en) Ligands
IL174218A0 (en) Ligands
GB0326077D0 (en) Productionised hydraulics
IL179980A0 (en) Asymmetrically substituted biaryldiphosphine ligands 1
IL179981A0 (en) Asymmetrically substituted biaryldiphosphine ligands 111
GB0115841D0 (en) Ligand
GB0323494D0 (en) Multi-head
GB0416392D0 (en) Multivalent polypeptide complexes
GB0327706D0 (en) Ligand
GB0328275D0 (en) Ligands